04:01 PM EDT, 04/02/2025 (MT Newswires) -- (Updates the headline and first paragraph with latest company filing.)

Novavax ( NVAX ) said Wednesday it is still awaiting a decision from the US Food and Drug Administration on its biologics license application for its Covid vaccine.

The vaccine approval is in limbo after the FDA missed a deadline, but a decision could be any day, The Wall Street Journal reported earlier.

The FDA previously allowed emergency use of Novavax's ( NVAX ) vaccine and the agency's decision would have determined whether to grant the vaccine a full approval, the report said, citing sources.

FDA did not immediately respond to requests for comment from MT Newswires.

NVAX shares were up 3% in recent trading.